Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLPG3067 single dose
GLPG3067 · 1 trial · 1 indication
To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.
To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.
To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.
| Arm | Type | Description |
|---|---|---|
| GLPG3067 single dose. | EXPERIMENTAL | Single Dose of GLPG3067 film coated tablets. |
| Name | Type | Description |
|---|---|---|
| GLPG3067 single dose | DRUG | GLPG3067 film coated tablets provided at Day 1. |
Inclusion Criteria: * Male subject ≥18 years of age on the day of signing the ICF. * A confirmed clinical diagnosis of CF. * Exocrine pancreatic insufficiency (documented in the subject's medical record). * Stable concomitant medication regimen for pulmonary health for at least 2 weeks prior to stu...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | Alyftrek, Trikafta, Ivacaftor, VX-272, Tezacaftor |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Roivant Sciences Ltd. | ROIV | 1 | PHASE1 | SP-101 |
GLPG3067 is an investigational small molecule developed by Lakefront Biotherapeutics (ticker: LKFT) for cystic fibrosis, a respiratory disease. It has been studied in a Phase 1 clinical trial and is not yet approved for any indication.
GLPG3067 is being developed as a treatment for cystic fibrosis. It is an investigational therapy that has completed a Phase 1 pharmacokinetic study in adult male subjects with the condition, but it has not been approved for clinical use.
GLPG3067 is developed by Lakefront Biotherapeutics, which trades under the ticker symbol LKFT. The company is responsible for the clinical development of this small molecule for cystic fibrosis.
GLPG3067 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not received FDA approval.
GLPG3067 has been evaluated in a single completed Phase 1 trial, NCT03589313, titled "Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis." The study enrolled 6 male participants in Belgium and was an uncontrolled, non-randomized design.
Yes, GLPG3067 is also referred to as GLPG3067 single dose. This alternative name reflects the single-dose pharmacokinetic study conducted in male subjects with cystic fibrosis.